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Crystal Structures of Oligomeric Forms
of the IP-10/CXCL10 Chemokine
minor) depending on the spacing of conserved cysteine
residues near the N terminus [15]. IP-10 is a member of
the CXC subfamily, in which the N-terminal cysteines
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mokine receptors, and CXC chemokines bind to CXC
chemokine receptors. Most receptors bind more than
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one chemokine, and, likewise, most chemokines bind
to more than one receptor. In the latter respect, IP-10
We have determined the structure of wild-type IP-10
is somewhat atypical, in that it specifically activates a
from three crystal forms. The crystals provide eight
single receptor, CXCR3 [17]. However, CXCR3 binds two
separate models of the IP-10 chain, all differing sub-
other interferon--induced, angiostatic CXC chemokines:
stantially from a monomeric IP-10 variant examined
monokine induced by interferon- (Mig; CXCL9) and inter-
previously by NMR spectroscopy. In each crystal form,
feron-inducible T cell  chemoattractant (I-TAC; CXCL11)
IP-10 chains form conventional  sheet dimers, which,
[17, 18].
in turn, form a distinct tetrameric assembly. The M form
The structural details of IP-10’s mechanism of action
tetramer is reminiscent of platelet factor 4, whereas
are crucial to further understanding IP-10-mediated pro-
the T and H forms feature a novel twelve-stranded 
cesses and to the development of IP-10/CXCR3-tar-
sheet. Analytical ultracentrifugation indicates that, in
geted therapeutics. IP-10’s action may involve oligomer-
free solution, IP-10 exists in a monomer-dimer equilib-
ization of the protein, as indicated by its potential to
rium with a dissociation constant of 9M. We propose
form dimers [19]. The precise role of this oligomerization
that the tetrameric structures may represent species
is not clear, as is the case with many other chemokines,
promoted by the binding of glycosaminoglycans. The
which are known to form dimers or higher oligomers in
binding sites for several IP-10-neutralizing mAbs have
concentrated (micromolar) solutions but are monomeric
also been mapped.
at physiological concentrations [20–23]. Furthermore, in
at least two of these cases, adoption of an oligomeric
structure is not a prerequisite for receptor binding orIntroduction
signal transduction [24, 25]. On the other hand, platelet
factor 4 (PF4; CXCL4) exists predominantly as a tetramerInterferon--inducible protein 10 kDa (IP-10; CXCL10)
is a chemoattractant cytokine (“chemokine”) secreted under physiological conditions and may act as such
[26]. In addition, IP-10 shares the ability to bind to cellby a diverse range of tissues under proinflammatory
conditions [1, 2]. It is a key mediator of the interferon surface glycosaminoglycans (GAGs) with most, if not
all, chemokines [27]. Chemokine-GAG interactions canresponse, preferentially attracts activated Th1 lympho-
cytes to sites of inflammation [3–5], and is an inhibitor of promote chemokine oligomerization [28] and the forma-
tion of immobilized chemokine gradients [28, 29], whichangiogenesis [6]. In addition, IP-10 is highly expressed in
a wide variety of diseases, including multiple sclerosis are likely to be important for chemokine action.
The structures of more than 20 chemokines have been[7, 8], rheumatoid arthritis, cardiac allograft rejection [9,
10], atherosclerosis [11], and sarcoidosis [12], making determined by X-ray crystallographic and/or NMR tech-
niques (including at least one member from each chemo-it a promising therapeutic target [13].
Chemokines, such as IP-10, are small, structurally re- kine subfamily). This includes the structures of the CXC
chemokines interleukin-8 (IL-8; CXCL8), PF4, and neu-lated proteins that play important roles in leukocyte traf-
ficking [14]. The approximately fifty known chemokines trophil-activating peptide-2 (NAP-2; CXCL7) [30–33], the
CC chemokines regulated on activation, normal T cellcan be divided into four subfamilies (two major and two
expressed and secreted (RANTES; CCL5) and monocyte
chemoattractant protein-1 (MCP-1; CCL2) [34–36], the
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Table 1. Crystallographic Statistics
M Form T Form H Form
Data Collection
Space group C2 P41212 P6522
Cell dimensions (a, b, c) (A˚) 139.0, 53.7, 53.4 59.4, 59.4, 121.7 84.6, 84.6, 117.0
(  105.7)
Resolution range (A˚) 20–3.0 50–1.92 50–2.0
Number of reflections
Measured 57,731 309,571 219,378
Unique 7,390 17,435 17,139
Completeness (%) 95.4 (92.8) 99.8 (100.0) 98.4 (99.8)
I/(I) 10.1 (2.6) 21.7 (3.2) 20.1 (3.3)
Rsym (%)a 9.6 (43.4) 8.7 (47.4) 7.8 (52.0)
Solvent content (%)b 55.4 60.3 64.6
Number of molecules per AUb 4 2 2
Refinement
Resolution range (A˚) 20–3.0 35–1.92 35–2.0
Number of reflections 7,367 15,343 14,624
Rcryst (%)c 26.7 27.9 26.4
Rfree (%)d 30.9 29.8 29.8
Number of atoms
Protein 1,959 888 1,111
Ligand 10 — —
Water — 42 78
Deviations from ideality (rms)
Bond lengths (A˚) 0.009 0.006 0.009
Bond angles () 1.7 1.2 1.6
Dihedral angles () 24.6 25.1 24.8
Improper angles () 1.61 0.77 1.09
Mean B factor by atom type (A˚2)
All 46.3 60.1 54.4
Protein main chain 45.8 58.8 53.1
Protein side chain 46.8 62.1 56.1
Ligand 54.6 — —
Water — 52.1 51.4
Parentheses enclose data for the outermost shell (3.11–3.00 A˚ for M form, 1.99–1.92 A˚ for T form, and 2.07–2.00 A˚ for H form).
a Rsym  hi[|Ii(h)  I(h)|/hiIi(h)], where Ii is the ith measurement and I(h) is the weighted mean of all measurements of I(h).
b Assuming a mean protein density of 1.34 g ml1.
c Rcryst  h|Fo  Fc|/hFo, where Fo and Fc are the observed and calculated structure factor amplitudes of reflection h.
d Rfree is equal to Rcryst for a randomly selected 6% subset of reflections excluded from refinement [53].
considerable differences in amino acid sequence, these the antibody binding sites on IP-10. These epitopes are
discussed in light of the structural information availableproteins possess remarkably similar three-dimensional
structures, and the generation of receptor specificity for IP-10.
from this common template is of great interest [38]. The
conserved scaffold consists of a three-stranded  sheet Results and Discussion
overlayed by an  helix, with many of the receptor bind-
ing residues located in the associated loops. Oligomer- Overview of the Structures
The structure of IP-10 was determined from three differ-ization provides an additional source of structural diver-
sity, with CXC and CC chemokines favoring different ent crystal forms: monoclinic (M), tetragonal (T) and hex-
agonal (H), at 3.0, 1.92, and 2.0 A˚ resolutions, respec-modes of association. Recently, the structure of a mono-
meric variant of IP-10 was determined by NMR spectros- tively (Table 1). The asymmetric unit of the M form
contains four copies of the IP-10 chain, whereas thosecopy [19]. This showed that IP-10 displays a typical
chemokine fold and identified residues involved in bind- of the T and H forms contain two copies. Each of the
three crystal forms presents a distinct tetrameric assem-ing a CXCR3-derived peptide but, by its nature, did not
examine the details of oligomerization. bly, formed by association of two pseudosymmetrical
dimers.We have determined the structure of wild-type IP-10
from three different crystal forms. In each case, the
monomeric units deviate surprisingly from the structure Features of the IP-10 Chain
The three structures provide eight independent modelsdetermined previously by NMR. The crystal structures
reveal three alternative tetrameric arrangements, two of of the IP-10 chain. In each model, the chain exhibits the
classical chemokine fold, stabilized by disulfide bondswhich are unprecedented among chemokines. These
higher oligomeric states may have implications for the between the two pairs of conserved cysteines (9:36 and
11:53; Figure 1). The cysteines of the CXC motif aremechanism of action of this chemokine. We have also
generated several IP-10-neutralizing mAbs and mapped flanked by extended loops, leading into a three-stranded
Oligomeric Forms of IP-10
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Figure 1. IP-10 Chain
(A) Schematic representation of chain A from the H form. Spheres denote the N and C termini of the model (residues 1 and 74, respectively).
(B) Superposition of the eight IP-10 models provided by the three crystal forms, along with the NMR structure of a monomeric variant of IP-
10 (Protein Data Bank code 1LV9, model 2 [19]), shown in stereo. The  carbon traces are shown and are colored as follows: M form, chain
A (red), chain B (orange), chain C (yellow), chain D (green); T form, chain A (light blue), chain B (pink); H form, chain A (dark blue), chain B
(purple); 1LV9, model 2, black. The two disulfide bonds in the H form A chain are shown in ball and stick representation.
(C) Amino acid sequence of IP-10 showing the position of the major secondary structure elements as present in the H form A chain.
antiparallel  sheet of the “Greek key” type. The third (Figure 1B): when all available  carbons are aligned,
the rms deviation ranges from 3.5 to 4.2 A˚. This can bestrand is connected to an amphipathic  helix, which lies
obliquely across the  sheet. Each of the eight models reduced to 2.0 A˚ only when optimized over 40 
carbons. The  strands are the best-aligned elements,presents a closely similar core structure (Figure 1B),
with the  carbons of any pair of models having an rms but there are significant differences here and throughout
the structure, notably in the orientation of the C-terminaldeviation of 	1.1 A˚. The similarities encompass the 
strands and the N, 30s, and 40s loops, but there are  helix and in the conformation of the 40s, 30s, and N
loops. Indeed, the backbones of the crystallographicallynotable differences in the N- and C-terminal regions,
indicating the high degree of flexibility permitted and determined chains resemble other chemokines far more
closely than they do the NMR structure of IP-10. Forthe influence of quaternary association at these sites.
The most complete models of the 77-residue IP-10 example, single chains from the crystal structures of
NAP-2 (Protein Data Bank code 1NAP [33]) and IL-8chain are derived from the H form, with chain A com-
prising residues 1–74 (Figure 1A) and chain B compris- (Protein Data Bank code 3IL8 [31]) offer particularly and
consistently good matches, with  carbons deviatinging residues 1–71. Here, the N-terminal loops and the
C-terminal helices are unusually well defined because 	1.4 A˚ (rms) over 
80% of the IP-10 chain. Thus, the
distortion of strand 2 noted by Booth et al. [19] is notof restraint upon oligomerization. In contrast, the models
derived from the T form lack eight or more residues from apparent in the IP-10 crystal structures, and the  sheet
and  helix are juxtaposed as in the prototypical CXCboth the N and C termini, with essentially only the core
residues discernible in electron density maps. In these chemokine, IL-8.
The topological differences induced in the IP-10 chainmodels, the undefined N termini (residues 1–8) appear
to extend into the solvent channel, and the C-terminal by oligomerization contrast with the minor differences
observed between the NMR structure of the analogoushelices are not as intimately involved in oligomerization.
The models from the M form are intermediate in com- monomeric IL-8 variant and the crystal structure of di-
meric IL-8 [40]. Here, the backbones of the NMR andpleteness, correlating with further differences in quater-
nary association. Of note are the residues toward the C crystal structures differ by a mere 1.2 A˚ (rms), with the
most significant effect of dimerization being the adop-terminus of the M form A chain, which are present in an
extended conformation with a short 310-helix taking the tion of a more extensive -helical structure toward the
C terminus. It appears that the structural constraintsplace of the longer  helix seen in the other crystal
forms. imposed on IP-10 by oligomerization are more far-reach-
ing than this and are not concentrated on the C-terminalTo enable comparison with the structure of the mono-
meric NMeLeu27 variant of IP-10 derived by NMR spec-  helix.
troscopy (Protein Data Bank code 1LV9; [19]), we se-
lected the most representative model from the NMR Features of the AB-type Dimer
All three structures show the association of IP-10 chainsensemble (model 2) using the cluster analysis program
NMRCLUST [39]. The crystallographically determined into tightly packed pseudosymmetrical dimers, desig-
nated here as AB-type dimers (Figure 2A). The A·B inter-IP-10 chains differ substantially from this NMR model
Structure
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Figure 2. AB-type Dimers of IP-10
(A) Schematic representation of the H form AB dimer. Chain A, blue; chain B, purple.
(B) Superposition of the four AB-type dimer models provided by the three crystal forms, along with selected CXC chemokines. The  carbon
traces are shown and colored as follows: M form, chains A and B (red); M form, chains C and D (green); T form, pink; H form, blue; PF4
(Protein Data Bank code 1RHP [32]), orange; NAP-2 (Protein Data Bank code 1NAP [33]), yellow; IL-8 (Protein Data Bank code 3IL8 [31]),
black.
face is formed by the association of the first  strand ences are reflected in the solvent-accessible surface
areas buried upon dimerization: 1290, 1410, 1010, andfrom opposing chains to generate a six-stranded anti-
1850 A˚2 for the M form AB, M form CD, T form, and H formparallel  sheet and by the antiparallel packing of the
dimers, respectively. Since the rather small interface ofopposing  helices on one face of the sheet. In these
the T form dimer is limited almost exclusively to the arearespects, the mode of association is identical to that of
between the  sheets, it is likely that the association ofthe prototypical “dimeric” CXC chemokine, IL-8 [30, 31].
these sheets is the main driving force for dimer forma-The three crystal forms provide four independent
tion. The other three dimers have interface areas compa-models of the AB-type dimer: two from the M form (di-
rable to those of other CXC chemokine dimers.mers AB and CD) and one from both the T and H forms.
These are all largely similar, as judged by  carbon
superposition (rms deviation between any pair 	1.2 A˚;
Features of the M Form Tetramer
Figure 2B) or by the rotation angle relating the two chains
Each of the three crystal forms presents a distinct tetra-
in the dimer (178.4–179.9), but display differences in
meric assembly, formed by association of two AB-type
the specific interactions at the interface. For all, the
dimers. In the M form, the tetramer is contained within
extent of main chain hydrogen bonding at the interface
the asymmetric unit. The AB-type dimers are arranged
is limited to reciprocal interactions between residues such that the two  sheets lie back to back, with the
Leu27 and Ile29. This is an unusually small region, since, C-terminal helices to the exterior (Figure 3A). Of the two
in most other CXC chemokine structures, four residues new symmetry axes formed, the one relating chains A
engage in reciprocal hydrogen bonds. The explanation and D is nearly exact (rotation angle, 178.2), but the
for this difference lies with the identity of residue 31 one relating chains A and C is not (rotation angle, 162.8),
in IP-10 (proline), which disrupts the  structure; the and, hence, the tetramer is asymmetric. This creates
corresponding position is occupied by a nonproline resi- two similar, asymmetric AC-type dimers (AC and DB),
due in the other reported structures. Nevertheless, the along with two unrelated AD-type dimers, whose halves
 carbon backbones of the IP-10 dimers deviate by just are noninteracting.
1.1–1.9 A˚ (rms) from those formed by IL-8 (Protein Data At the A·C interface, opposing N-terminal regions in-
Bank code 3IL8 [31]), PF4 (Protein Data Bank code 1RHP teract, forming a short antiparallel sheet (Figure 3A). These
[32]), or NAP-2 (Protein Data Bank code 1NAP [33]) segments are further stabilized by strong hydrogen
over 
80% of their lengths (Figure 2B). bonds with two sulfate ions derived from the crystalliza-
Additional stabilization of the interface is provided by tion medium, giving a relatively well-defined structure
electrostatic interactions between the side chains of to this region. The interface also features hydrophobic
opposing Lys26 and Glu28 residues and by hydrophobic interactions between strand 3 of the C chain and the
interactions, chiefly between the opposing  strands 30s loop of the A chain, contributing to a reduction in
and  helices. The extent of these interactions, however, solvent-accessible surface area of 1110 A˚2 for the A·C
differs among the four models. The H form lies at one association. Although the DB dimer is very similar (
extreme, with contact between the helices extending all carbon rms deviation, 0.75 A˚), the D·B interface is con-
the way out to SerA73 (a residue that is not discernible siderably smaller (540 A˚2 ), involves relatively few interac-
in the other models). The T form lies at the other extreme, tions, and leaves the N termini of these chains more
with involvement of the helices restricted to a single disordered.
residue (ValA68), a large portion of each helix being in The tetrameric arrangement in the M form is reminis-
cent of, but subtly different from, those found in thea disordered state (Figure 2B). These structural differ-
Oligomeric Forms of IP-10
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Figure 3. Orthogonal Views of the Three IP-10 Tetramers
(A) M form; (B) T form; (C) H form. For each form, two schematic representations are shown, related by a 90 rotation about the x axis. For
the M form, two sulfate ions from the crystallization medium are shown in yellow, in ball and stick representation.
crystal structures of PF4 [32] and NAP-2 [33]. These loop and the tips of the other strands make hydrophobic
interactions with other residues of the N loop. No elec-tetramers are also formed by the asymmetric associa-
tion of two AB-type dimers, but the dimers are juxta- trostatic interactions are involved. The B·B association
reduces the solvent-accessible surface area by 1290 A˚2 ,posed differently. In contrast to the M form tetramer,
the axis relating chains A and C is almost perfect (rota- a figure greater than that for the A·B association in this
crystal form.tion angle, 179), while the axis relating chains A and
D is not (rotation angle,170), i.e., the source of asym- The H form tetramer can be considered as an embel-
lishment of the T form tetramer. The 4 displacement ofmetry is different. As a consequence, every chain makes
contact with every other chain, with only one interchain the A and B chains has only a minor effect on the B·B
interface but brings the A and B (A and B) chainsinterface being related to the M form A·C interface (B·D
in each case). together to form additional interchain contacts (Figure
3C). These new interfaces are formed primarily by the
asymmetric association of the opposing N-terminal/NFeatures of the T and H Form Tetramers
In both the T and H form tetramers, the six-stranded 
sheets of two AB-type dimers associate through their
3 strands to form a twelve-stranded antiparallel sheet
(Figures 3B and 3C). This “super sheet” has a sharp kink
in the middle, forming an open barrel-like structure with
the C-terminal helices to the exterior. The arrangement is
considerably different from that of the M form tetramer.
Indeed, this is the first time that this type of arrangement
has been observed among chemokines.
For both the T and H form tetramers, the symmetry
axis relating the pair of AB-type dimers coincides with
a crystallographic symmetry axis. Hence, in the crystals,
chains A and A are identical copies related by a 180
rotation, as are chains B and B. Chains A and B (A
and B), however, are not related by symmetry and are
instead related by rotations of 149.8 and 153.8 in the
T and H forms, respectively. These tetramers are, there-
fore, no more symmetrical overall than is the M form
tetramer.
The T form exhibits the simplest mode of association:
Figure 4. Sedimentation Equilibrium Analysis of IP-10chains B and B simply pair up symmetrically via their 3
Equilibrium distribution of 12 M IP-10 after 12 hr at 30,000 rpmstrands (Figure 3B). A total of four main chain hydrogen
(open circles). By varying the initial protein concentration and thebonds are made in an antiparallel fashion between resi-
rotor speed, a total of nine different runs were performed. All data
dues 49, 51, and 53 of each chain. At the periphery of the were fitted simultaneously to a reversible monomer-dimer associa-
interface, the side chain of Lys51 makes two hydrogen tion model, shown here as a solid curve with the residuals as solid
circles. Absorbance was measured at 230 nm.bonds with Thr10 in the opposing N loop, while the 40s
Structure
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Figure 5. Anti-IP-10 Monoclonal Antibodies
Neutralize IP-10 Function In Vitro
(A) Chemotactic response of CXCR3-300-19
cells to IP-10, assayed in a Boyden chamber
in the presence or absence of the indicated
mAbs.
(B) Calcium mobilization in CXCR3-300-19
cells, measured following stimulation with IP-
10 in the presence or absence of D1D2 or
W3F5 mAbs. The data is presented as the
ratio of light emitted at 510 nm after excitation
at 340 nm relative to that emitted after excita-
tion at 380 nm.
loop regions, aided by hydrophobic interactions be- Association of chemokine chains through N-terminal
residues is more commonly associated with dimerictween the surrounding segments. The solvent-accessi-
ble surface area is reduced by 1310 A˚2 for each of the forms of CC chemokines such as RANTES [34], which
likewise feature antiparallel main chain hydrogen bond-two copies of this interface in the tetramer, a consider-
able sum. ing at the dimer interface. The CC chemokines differ,
however, in that their N-terminal dimers are alwaysAn alternative view is that the T form tetramer is essen-
tially an intermediate en route to the H form. Thus, as- highly (if not perfectly) symmetrical, significantly affect-
ing the displacement of the two chains. Nevertheless,sembly of the H form tetramer may begin with the associ-
ation of the 3 strands, after which the N-terminal on surveying the three IP-10 tetramers, it is apparent
that IP-10 is capable of employing its N terminus andinteractions develop. The only precedent for the associ-
ation of 3 strands is provided by the tetrameric form several other parts of its polypeptide chain for the forma-
tion of multiple oligomeric forms.of the CC chemokine MCP-1 (Protein Data Bank code
1DOL [36]). This tetramer is perfectly symmetrical and
features three types of interchain interface. At one of Analytical Ultracentrifugation
these, the 3 strands interact, although the arrangement In order to determine the likely association state of IP-10
is out of step with the IP-10 interface, is far less exten- in biological fluids, a sedimentation equilibrium analysis
was performed in 0.15 M NaCl and 0.02 M sodium phos-sive, and involves only two main chain hydrogen bonds.
Oligomeric Forms of IP-10
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Figure 6. Binding of Monoclonal Antibodies
to Recombinant IP-10 Protein (1–77) and IP-
10-Derived Synthetic Peptides
(A) Top, amino acid sequences of the IP-10
derived peptides, P1–P4. Bottom, dot blot
analysis. IP-10 and derived peptides were
spotted onto nitrocellulose membranes in the
indicated pattern and incubated with the indi-
cated anti-IP-10 monoclonal antibodies. The
filters were developed with an anti-mouse IgG
horseradish peroxidase-conjugated second-
ary antibody and ECL reagents.
(B) ELISA. IP-10 and derived peptides were
immobilized to 96-well ELISA plates. The in-
dicated monoclonal antibodies were then
assayed for binding to IP-10 and the IP-10-
derived peptides. The mean OD650 of dupli-
cate samples recorded after 15 min is shown.
phate buffer (pH 7.4). The data fitted a reversible mono- G protein-coupled receptor, CXCR3 [17]. In order to
determine the epitope or epitopes of IP-10 responsiblemer-dimer association model (Figure 4), yielding a disso-
ciation constant of 9 M and indicating that the for CXCR3 activation, we raised monoclonal antibodies
against IP-10. Some of these antibodies were thenmonomeric form will predominate in free solution under
physiological conditions. The CXC chemokines MIP-2, tested for their ability to block IP-10-induced chemo-
taxis and calcium influx. Two antibodies, D1D2 andIL-8, NAP-2, and SDF-1 have been studied by similar
means under similar conditions, yielding dissociation W2D4, inhibited chemotaxis and calcium flux, whereas
another, W3F5, inhibited chemotaxis but had no effectconstants of 4, 14, 53, and 150 M, respectively [20, 22,
41]. In addition, the association state of PF4 has been on calcium flux (Figure 5). In order to map the epitopes
on IP-10 recognized by these antibodies, we synthe-studied by 1H NMR spectroscopy, revealing that, under
most solvent conditions, the tetrameric form predomi- sized peptides corresponding to different regions of IP-
10 and tested the antibodies for their ability to bind tonates [26]. Thus, the solution behavior of IP-10 is compa-
rable with that of the more tightly associating dimeric these peptides. D1D2 and W2D4 each bound specifi-
cally to a peptide corresponding to residues 20–36 ofCXC chemokines, but not with that of PF4. However, a
gel filtration-based approach has shown that the inter- IP-10, while W3F5 bound only to intact IP-10 (Figure 6).
These results implicate residues contained within IP-action of chemokines with GAGs can shift the equilib-
rium toward oligomerization significantly [28] and, 10 positions 20–36 as the binding site for two mAbs
that are inhibitory to receptor-mediated chemotaxis andhence, the monomeric forms may constitute a signifi-
cantly smaller fraction of the population in vivo. This is calcium flux. This residue range is centered on the 1
strand and extends out to include the last four residuesdiscussed further below.
of the N loop and the first six residues of the 30s loop.
The segment has limited overlap with the set of residuesCXCR3-Interacting Regions
The effects of IP-10 on activated Th1 lymphocytes are (positions 7, 8, 17, 19, 34, 38, and 44) perturbed by the
presence of a peptide derived from the N terminus ofmediated through specific interactions with its cognate
Structure
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Figure 7. Functional Residues of IP-10
(A) Potential CXCR3 binding residues. The H form A chain is drawn in surface representation. Residues perturbed by the presence of a CXCR3-
derived peptide [19] are in pink. The areas aligning with IL-8’s CXCR1 binding region [42] are in yellow, and the backbone of the corresponding
CXCR1-derived peptide is traced in red. The segment of IP-10 (residues 20–36) recognized by the receptor-blocking mAbs D1D2 and W2D4
is colored in two shades of blue, with the lighter shade highlighting the areas of overlap with the above studies (much of this segment is
located on the face opposite to that shown).
(B) Potential glycosaminoglycan binding residues. Left, M form; right, H form. For each form, two views are shown, related by a 180 rotation
about the y axis (the upper view is the same as in the corresponding upper panel of Figure 3). The molecular surfaces are drawn with basic
residues analogous to the glycosaminoglycan binding residues of PF4 (IP-10 residues Arg22, Lys46, Lys47, Lys48, Lys62, and Lys66) in green.
CXCR3 [19] or with those residues in IL-8 (two patches also binds to heparin fairly strongly, with interactions
focused on Lys20 and on the C-terminal helix at residuesbounded by positions 8/21 and 40/49) that make contact
with an analogous peptide derived from CXCR1 [42]. Arg60, Lys64, Lys67, and Arg68 [45]. In IP-10, the equiva-
lent regions include residues Arg22, Lys46, Lys47,One possibility is that the binding of D1D2 and/or W2D4
obstructs the N loop where it forms part of a cleft in Lys48, Lys62, and Lys66. When mapped onto the sur-
face of the M form tetramer, these residues form a ringconcert with the 40s loop on the surface of both IL-8
[42] and IP-10 (Figure 7A). If the partners in the IP- comparable with the heparin binding residues of PF4
(Figure 7B), and it is therefore possible that this form of10·CXCR3 complex are oriented in a manner similar to
those in the IL-8·CXCR1 complex, obstruction of this IP-10 can bind heparin in the same manner as does PF4.
In the H and T forms, these residues also circumnavigateloop might be expected to block the IP-10·CXCR3 inter-
the surface but follow a less contiguous and more con-action. Alternatively, the antibodies may obscure part
voluted path (Figure 7B).of the 30s loop, this being one of the CXCR3 binding
In vivo, some chemokines are secreted ready com-regions identified by NMR spectroscopy [19]. Interest-
plexed with GAG-bearing proteoglycans [46, 47], whileingly, this region is discrete from the IL-8·CXCR1 peptide
many others encounter immobilized proteoglycansinterface, suggesting that the N-terminal segment of
upon contact with the extracellular matrix [29] or appro-CXCR3 may take a different path across the surface of
priately decorated cells [27]. The effects of GAGs onIP-10 (Figure 7A). At least one copy of the face of IP-10
chemokine activity are generally not well understood,highlighted in Figure 7A is preserved on the surface of
but the presence of cell surface GAGs is known to beeach of the tetrameric forms, suggesting that, if assem-
necessary for the anti-HIV activity of RANTES [47, 48],bled, these oligomers may retain their receptor binding
suggesting that some biological activities can be signifi-properties.
cantly modulated. In the case of IP-10, GAG-dependent
aggregation of the protein has been detected on the
Glycosaminoglycan Binding Residues surface of cells of various types, and this is likely to be
IP-10 possesses several residues that form basic clus- important for local retention and possibly also for the
ters that, by analogy with other CXC chemokines such mechanism of its angiostatic action [27]. Oligomeriza-
as PF4 and IL-8, are implicated in GAG binding [43]. PF4 tion of IP-10 is not a prerequisite for this binding but
binds to heparin particularly strongly, with interactions could conceivably follow as a consequence, as has been
focused on the Arg-Pro-Arg-His motif at positions 20–23 observed in vitro with other chemokines, including IL-8,
at the N loop/1 junction, along with Lys46 and Arg49 MCP-1, and RANTES [28]. Although the incidence of
in the 2/40s loop region and several lysine residues oligomerization in vivo is unclear, characterization of the
from the C-terminal helix [44]. In the three-dimensional process is of great value to future clinical applications
structure of PF4, these residues form a ring around the where the local concentration may be high. This is
evidenced by the difference in anti-HIV activity ob-tetramer, perpendicular to the C-terminal helices. IL-8
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of the -stranded core of the human PF4 AB dimer (Protein Dataserved between wild-type and disaggregated RANTES
Bank code 1RHP [32]) to the M form data, we obtained two solutions,variants [49].
one with a correlation coefficient of 48.3% and an R factor of 49.1%The tetrameric structures described in this report indi-
and the other with a correlation coefficient of 43.4% and an R factor
cate that, in an appropriately stabilizing environment, of 51.6%. After a single round of refinement with CNS [52], the R
a range of ordered, multimeric IP-10 species can be factor dropped to 39% (free R factor, 44% [53]). Using this refined
model as a search model, we obtained clear molecular replacementsupported. The spatial distribution of putative heparin
solutions for the T and H form data in space groups P41212 andbinding residues suggests that binding to GAGs such
P6522, respectively.as heparin might provide this stabilization. It is also
For all of the crystal forms, noncrystallographic symmetry re-possible that GAG-dependent IP-10 association differs
straints were imposed on the initial models, but, as refinement pro-
substantially from GAG-independent association, and ceeded, restraints were relaxed and finally removed. Each cycle of
future work will address the fine structure of IP-10·GAG refinement consisted of rigid body refinement, positional refinement,
B factor refinement (individual or group), and simulated annealingcomplexes.
incorporating the slow cool protocol [54], with bulk solvent and
anisotropic B factor correction. Model building was performed be-Biological Implications
tween refinement cycles with O [55]. Water molecules were incorpo-
rated into the T and H form models where appropriately positioned
IP-10 is a chemokine secreted by a diverse range of 3  electron density was present in Fo – Fc electron density maps.
tissues under proinflammatory conditions and is a prom- Those residues lacking side chain density in 2Fo – Fc electron density
maps were truncated at C, and residues for which there was noising therapeutic target. By binding to its receptor
discernible density were omitted. The final refinement statistics are(CXCR3), IP-10 preferentially attracts activated Th1 lym-
given in Table 1.phocytes to sites of inflammation. The three-dimen-
The final M form model comprises residues A3–A69, B9–B70,
sional structures of IP-10 described herein provide a C7–69, and D8–69, with SerA69, LysB48, and LysC48 truncated at
framework for the design of therapeutics targeted to IP- C; the T form model comprises residues A9–A68 and B9–B63, with
10/CXCR3-associated processes. The topology of the residue IleA61 truncated at C; and the H form model comprises
residues A1–A74 and B1–B71, with residues LysA70, LysA74,IP-10 polypeptide chain is that of a typical CXC chemo-
LysB48, and LysB70 truncated at C. For each model, all residueskine, and we have been able to highlight regions that
lie within allowed regions of the Ramachandran plot.are involved in receptor interactions through the use of
Structural alignments were performed with the European Bioinfor-
specific monoclonal antibodies. Unusually, IP-10 can matics Institute Structure Matching tool (http://www.ebi.ac.uk/
adopt a variety of multimeric forms whose formation msd-srv/ssm/) and LSQMAN [56]. Secondary structures were identi-
may be promoted by glycosaminoglycans at various fied with PROMOTIF [57], and figures were created with PyMOL
(DeLano Scientific, San Carlos, CA).sites of action. Their physiological relevance is unclear
at present, but they warrant further investigation.
Analytical Ultracentrifugation
Sedimentation equilibrium experiments were performed with aExperimental Procedures
Beckman XL-A analytical ultracentrifuge equipped with an AN60 Ti
rotor. Samples were prepared in 0.15 M NaCl and 0.02 M sodiumCrystallization and Diffraction Measurements
phosphate buffer (pH 7.4) and loaded into cells containing EponHuman IP-10 from recombinant E. coli was purchased from Pepro-
six-channel centerpieces of 12 mm path length with quartz windows.tech EC (UK) as a lyophilized powder. Crystals of IP-10 were grown
Runs were carried out at 20C with protein concentrations of 2.3,in hanging drops by mixing equal volumes of protein solution (10 mg
4.4, and 12 M at each of three rotor speeds: 30,000, 35,000, andml1 in water) and reservoir solution. Thin, rod-shaped monoclinic (M
45,000 rpm. Since IP-10 has negligible absorbance at 280 nm, cellsform) crystals were obtained from PEG solutions over a wide pH
were monitored at 230 nm. Each cell was scanned after a period ofrange (approximately 3–8). Diffraction quality crystals grew within
12 hr, at which point equilibrium had been reached. This was con-48 hr at 16C with a reservoir solution consisting of 0.1 M sodium
firmed by reference to a second scan recorded after an additionalacetate buffer (pH 4.4), 16% PEG 4000, and 0.2 M (NH4)2SO4. Large,
6 hr.hexagonal (H form) and tetragonal (T form) crystals were obtained
Data were excised from the traces and fitted globally with thewith a reservoir solution consisting of 0.1 M Tris-HCl buffer (pH 8.75)
manufacturer’s software to both a single species modeland 3.3 M sodium formate. Both crystal forms appeared within 24
hr at 16C in the same drop and could be easily distinguished by
their morphologies. Prior to data collection, all crystals were trans- Cr  C0 · exp  
2
2RT
M(1  v)(r 2  r 20 )  E (1)
ferred to a cryoprotectant solution composed of 75% mother liquor
and 25% glycerol.
and a self-associating dimerization modelFor the M form, a 3 A˚ resolution data set was collected at 100 K
on station X11 of DESY at EMBL, Hamburg, Germany, with a MAR
Cr  C0 · exp  
2
2RT
M(1  v)(r 2  r 20 )  KaC02345 image plate detector. The crystal belonged to space group C2.
For the T and H forms, annealing the crystals in the cryoprotectant
solution for 3–5 min enabled the collection of data sets at 1.92 and
· exp 
2
RT
M(1  v)(r 2  r 20 )  E (2)2.0 A˚ resolutions, respectively. These data were collected at 100 K
on station PX14.1 of the SRS, Daresbury, UK, equipped with an
ADSC Quantum-4 CCD detector. On the basis of systematic ab- where Cr and C0 are the concentrations at radius r and at the refer-
sences, the space groups of the T and H forms were determined ence radius r0,  is the angular velocity, R is the gas constant, T is
to be either P41212/P43212 or P6122/P6522, respectively. By reference the absolute temperature, M is the molecular mass of the monomeric
to the solvent content and Matthews coefficient [50], we deduced species (calculated from the amino acid sequence),  is the partial
that the M form contained four IP-10 chains per asymmetric unit, specific volume,  is the solvent density, E is the baseline offset, and
whereas the T and H forms contained two. More details of data Ka is the association constant for the monomer-dimer equilibrium.
collection and processing are given in Table 1. Protein concentration was determined with the assumption that
230  17000 M1 cm1, derived by correlation of stock solution
absorbance with protein concentration estimation by the bicinchoni-Structure Determination
The structures were determined by the molecular replacement nic acid method [58] with bovine serum albumin as calibration stan-
dard. The partial specific volume and solvent density were deter-method with AMoRe [51]. By applying a homology model consisting
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mined to be 0.7512 ml g1 and 1.006 g ml1, respectively, by the at Daresbury, UK, and EMBL/DESY, Hamburg, Germany, for their
help with X-ray data collection. We acknowledge the Europeanmethod of Laue, as implemented in SEDNTERP [59].
Community—Access to Research Infrastructure Action of the Im-
proving Human Potential Programme support to the EMBL HamburgAntibodies
Outstation contract number HPRI-1999-CT-000017 and Dr. D.J.Monoclonal antibodies to human IP-10 were generated with Balb/C
Scott (University of Bristol, UK) for analytical ultracentrifugation datamice injected with recombinant human IP-10 [27]. Hybridoma cells
collection.producing antibodies to IP-10 were isolated on the basis of specific
immunoreactivity to recombinant human IP-10, but not to other
chemokines, including Mig, I-TAC, IL-8, and SDF-1 (Peprotech, Received: November 26, 2002
Rocky Hill, NJ), in ELISA and Western blot assays. Hybridomas Revised: February 24, 2003
were grown in serum-free media, and monoclonal antibodies were Accepted: March 5, 2003
purified by protein G-Sepharose chromatography. Published: May 6, 2003
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